Neutralizing antibodies for SARS-CoV-2 infection.
Rev Esp Quimioter
; 35 Suppl 3: 16-19, 2022 Oct.
Article
in English
| MEDLINE | ID: covidwho-2251897
ABSTRACT
The COVID-19 pandemic has boosted significant research in developing monoclonal antibodies (mAbs) to treat and prevent SARS-CoV-2 infection. Clinical trials have shown that mAbs are safe and effective in preventing hospitalization and death in patients with mild to moderate COVID-19 risk factors for progression. mAbs have also been effective for treating severe disease in seronegative patients and preventing COVID-19. So far, studies have been carried out in a largely unvaccinated population at a time when the omicron variant was not described. Future research should address these limitations and provide information on specific population groups, including immunosuppressed and previously infected individuals.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antibodies, Neutralizing
/
COVID-19
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Topics:
Variants
Limits:
Humans
Language:
English
Journal:
Rev Esp Quimioter
Journal subject:
Drug Therapy
Year:
2022
Document Type:
Article
Affiliation country:
Req
Similar
MEDLINE
...
LILACS
LIS